Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 5/20 | 0.51 |
| ▸ | HRH1 | P35367 | 6/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.48 |
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | HTR2C | P28335 | 4/20 | 0.48 |
| ▸ | HTR2B | P41595 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PTAFR | P25105 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2604746 | 0.91 | SETD7 (0.51) | SETD7HRH1CHRM2CHRM1HTR1A | |
| SCHEMBL6988373 | 0.86 | HRH1 (0.61) | HRH1CHRM2KCNH2HTR2AHTR2B | |
| SCHEMBL6990036 | 0.83 | SETD7 (0.48) | SETD7HRH1CHRM2CHRM1HTR1A | |
| SCHEMBL6990642 | 0.81 | MAPK1 (0.52) | SETD7HRH1CHRM2CHRM1HTR1A | |
| SCHEMBL6990645 | 0.81 | MAPK1 (0.52) | SETD7HRH1CHRM2CHRM1HTR1A | |
| SCHEMBL27300170 | 0.81 | SETD7 (0.48) | SETD7HRH1CHRM2CHRM1HTR1A | |
| SCHEMBL7092907 | 0.81 | SETD7 (0.56) | SETD7HRH1CHRM2CHRM1HTR1A | |
| SCHEMBL5060512 | 0.80 | SETD7 (0.52) | SETD7HRH1CHRM2CHRM1HTR1A | |
| Alcaftadine SCHEMBL1602418 | 0.80 | SETD7 (0.52) | SETD7HRH1CHRM2CHRM1HTR1A | |
| Alcaftadine SCHEMBL29378093 | 0.80 | SETD7 (0.52) | SETD7HRH1CHRM2CHRM1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139531-A1 | USE OF CONNECTIVE TISSUE MAST CELL STABILIZERS TO FACILITATE OCULAR SURFACE RE-EPITHELIZATION AND WOUND REPAIR | ALCON MANUFACTURING LTD. (US) | 2008-06-12 | — | — | US | claimed |
| CN-1142360-A | A method for preparing a medical composition conpaining imidazo[2,1-b][3] benzo azepine dericvants | YUAN ANLING (CN) | 1997-02-12 | — | — | CN | claimed |
| US-5468743-A | Imidazo[2,1-b]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-11-21 | — | — | US | claimed |
| EP-0588858-A1 | IMIDAZO 2,1-b] 3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-03-30 | — | — | EP | claimed |
| WO-1992022551-A1 | IMIDAZO[2,1-b][3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-23 | — | — | WO | claimed |
| EP-0518435-A1 | Imidazo[2,1-b][3]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-16 | — | — | EP | claimed |
| US-20250108059-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | JOHNSON & JOHNSON VISION CARE, INC. | 2025-04-03 | — | — | US | disclosed |
| US-20240058355-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | JOHNSON & JOHNSON VISION CARE, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230181594-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | JOHNSON & JOHNSON VISION CARE (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181594-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | JOHNSON & JOHNSON VISION CARE (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181594-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | JOHNSON & JOHNSON VISION CARE (US) | 2023-06-15 | — | — | US | disclosed |
| US-20210030762-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | JOHNSON & JOHNSON VISION CARE, INC. | 2021-02-04 | — | — | US | disclosed |
| US-20210030762-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | JOHNSON & JOHNSON VISION CARE, INC. | 2021-02-04 | — | — | US | disclosed |
| WO-2007117971-A2 | OCULAR ALLERGY TREATMENTS | VISTAKON PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-0588858-B1 | IMIDAZO 2,1-b] 3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA NV (BE) | 2003-09-17 | — | — | EP | disclosed |
| CN-1142360-A | A method for preparing a medical composition conpaining imidazo[2,1-b][3] benzo azepine dericvants | YUAN ANLING (CN) | 1997-02-12 | — | — | CN | disclosed |
| US-5468743-A | Imidazo[2,1-b]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-11-21 | — | — | US | disclosed |
| EP-0588858-A1 | IMIDAZO 2,1-b] 3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-03-30 | — | — | EP | disclosed |
| WO-1992022551-A1 | IMIDAZO[2,1-b][3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-23 | — | — | WO | disclosed |
| EP-0518435-A1 | Imidazo[2,1-b][3]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181594-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | CCL11, HRH2, IL5 | SETD7 2348/4885HRH1 7/4885CHRM2 1362/4885 |
| US-20080139531-A1 | USE OF CONNECTIVE TISSUE MAST CELL STABILIZERS TO FACILITATE OCULAR SURFACE RE-EPITHELIZATION AND WOUND REPAIR | CMA1, LTK, KIT | SETD7 2278/4885HRH1 35/4885CHRM2 437/4885 |
| US-20250108059-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | CCL11, HRH2, IL5 | SETD7 2348/4885HRH1 7/4885CHRM2 1362/4885 |
| US-20240058355-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | CCL11, HRH2, IL5 | SETD7 2348/4885HRH1 7/4885CHRM2 1362/4885 |
| US-20210030762-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | CCL11, HRH2, IL5 | SETD7 2348/4885HRH1 7/4885CHRM2 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.